LO3 (LO3) News
Follow LO3 (LO3) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Lonza Reorganizes, Sells CHI and Announces CHF500 Million Buyback
EQUITY | Oct 14, 2026, 07:02 AM UTC
M
Lonza Sets Mid-Term Targets, Confirms 2026 Outlook
Lonza set new mid-term targets and confirmed its 2026 outlook ahead of its capital markets day. It said third-quarter performance was in line with expectations across its business areas.
EARNINGS | Oct 14, 2026, 05:33 AM UTC
M
Lonza Raises Long-Term Sales Growth Target to Low Teens
Lonza targets average organic sales growth in the low teens over time at constant exchange rates and aims to accelerate core EBITDA margin expansion, targeting a margin in the high thirties over the medium term.
EARNINGS | Oct 14, 2026, 05:22 AM UTC
M
Lonza Targets Core EBITDA Margin in High Thirties Medium Term
Lonza now aims for a core EBITDA margin in the high thirties over the medium term.
EARNINGS | Oct 14, 2026, 04:44 AM UTC
M
Lonza Raises Sales Growth Target to Low-Teens Organic Growth
Lonza raised its sales growth target to low-teens organic growth on average over time.
EARNINGS | Oct 14, 2026, 04:43 AM UTC
L
Lonza Group Ltd (LO3) Nominates Pearl Huang to Board
Lonza nominated Pearl Huang as an independent Board member, subject to election at the May 2027 AGM; she would join the Strategy and Innovation and Remuneration Committees. Two long-serving directors will not stand for r
NEWS | Sep 30, 2026, 05:03 AM UTC
L
Lonza: Angelica Kohlmann and Christoph Maeder Won't Stand for Re-Election at 2027 AGM
Lonza: Angelica Kohlmann and Christoph Maeder Won't Stand for Re-Election at 2027 AGM
NEWS | Sep 30, 2026, 05:01 AM UTC
L
Lonza Nominates Pearl Huang as Independent Board Member
Lonza Nominates Pearl Huang as Independent Board Member
NEWS | Sep 30, 2026, 05:00 AM UTC
L
Lonza Group: Strong CDMO demand, margin focus, and disciplined M&A drive growth amid tightening capacity
CDMO demand remains robust, with strategic focus shifting to pure-play operations and disciplined M&A. Specialized Modalities rebounded in 2026, while Integrated Biologics growth aligns with capacity cycles. Margin and f
MNA | Sep 15, 2026, 04:06 PM UTC
L
Lonza Group: Transition to a focused CDMO, with robust demand and disciplined growth, underpins a positive outlook
Strong demand from pharma and biotech supports a positive outlook, with a strategic shift to a pure-play CDMO and disciplined M&A. Specialized Modalities rebounded in 2026, while Integrated Biologics growth aligns with c
EARNINGS | Sep 15, 2026, 03:59 PM UTC
L
Lonza to expand U.S. manufacturing with new Oregon site
Lonza Group said it is expanding its U.S. manufacturing footprint with a new facility in Oregon. The company said the new site aims to meet growing U.S. demand and supports efforts to build more resilient pharmaceutical
EQUITY | Sep 10, 2026, 07:01 AM UTC
L
Lonza to add commercial spray-drying facility in Oregon
EQUITY | Sep 10, 2026, 05:03 AM UTC